Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;28(1):e301-e304.
doi: 10.1097/RHU.0000000000001707.

Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children

Jordan E Roberts  1 , Peter A Nigrovic, Mindy S Lo  1 , Margaret H Chang  1
Affiliations

Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children

Jordan E Roberts et al. J Clin Rheumatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. J.E.R. was supported by NIH grant 5T32AI007512-34. P.A.N. was supported by NIH grant P30AR070253. M.H.C. was supported by a Rheumatology Research Foundation Scientist Development Award, NIH/NIAID T32AI007512, NIH/NICHD K12HD052896, a Joint Biology Consortium microgrant off parent grant NIH/NIAMS P30AR070253, and a Translation Accelerator Grant from the Human Skin Disease Research NIH/NIAMS P30AR069625.

Figures

FIGURE.
FIGURE.
Patient cohort. Flowchart indicating the number of patients with refractory uveitis who switched from adalimumab Q2 weeks to each arm of the study (adalimumab Q1 week or infliximab) and the portion who achieved disease control on the indicated medications.
See this image and copyright information in PMC

References

    1. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192. - PubMed
    1. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943. - PubMed
    1. Ramanan AV Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–1646. - PubMed
    1. Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J AAPOS. 2016;20:145–147. - PubMed
    1. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37:549–553. - PubMed